243 related articles for article (PubMed ID: 35502366)
1. Prognostic usefulness of clinical features and pretreatment
Chen D; Tang M; Lv S; Wang H; Du W; Zhao X; Lin L; Zhu Y; Wang G; Zhu H; Zhao K
Quant Imaging Med Surg; 2022 May; 12(5):2792-2804. PubMed ID: 35502366
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer.
Liao S; Penney BC; Wroblewski K; Zhang H; Simon CA; Kampalath R; Shih MC; Shimada N; Chen S; Salgia R; Appelbaum DE; Suzuki K; Chen CT; Pu Y
Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):27-38. PubMed ID: 21946983
[TBL] [Abstract][Full Text] [Related]
3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
[TBL] [Abstract][Full Text] [Related]
5. [Prognostic value of pretreatment (18)F-FDG PET-CT metabolic parameters in patients with advanced extranodal NK/T cell lymphoma].
Wu LL; Liang JH; Wang L; Xu W; Ding CY
Zhonghua Zhong Liu Za Zhi; 2019 Nov; 41(11):831-836. PubMed ID: 31770850
[No Abstract] [Full Text] [Related]
6. Prognostic significance of metabolic tumor volume and total lesion glycolysis in patients with advanced cervical carcinoma.
Calles-Sastre L; Mucientes-Rasilla J; San-Frutos Llorente LM; Royuela A; Garcia-Espantaleón Navas M; Herrero Gámiz S; Pérez-Medina T
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2019; 38(1):17-21. PubMed ID: 30366731
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Value of Pretreatment Metabolic Tumor Volume and Total Lesion Glycolysis Using 18F-FDG PET/CT in Patients With Metastatic Renal Cell Carcinoma Treated With Anti-Vascular Endothelial Growth Factor-Targeted Agents.
Hwang SH; Cho A; Yun M; Choi YD; Rha SY; Kang WJ
Clin Nucl Med; 2017 May; 42(5):e235-e241. PubMed ID: 28288043
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Value of Quantitative Parameters of
Kato A; Nakamoto Y; Ishimori T; Saga T; Togashi K
AJR Am J Roentgenol; 2020 Mar; 214(3):649-657. PubMed ID: 31939696
[No Abstract] [Full Text] [Related]
9. Predictive value of clinical characteristics and baseline
Huang W; Chao F; Li L; Gao Y; Qiu Y; Wang W; Gao J; Han X; Kang L
Quant Imaging Med Surg; 2023 Dec; 13(12):8571-8586. PubMed ID: 38106313
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of standardized uptake value and metabolic tumour volume on ¹⁸F-FDG PET/CT in oropharyngeal squamous cell carcinoma.
Kim JW; Oh JS; Roh JL; Kim JS; Choi SH; Nam SY; Kim SY
Eur J Nucl Med Mol Imaging; 2015 Aug; 42(9):1353-61. PubMed ID: 26067088
[TBL] [Abstract][Full Text] [Related]
11. The Use of
Hlongwa KN; Mokoala KMG; Matsena-Zingoni Z; Vorster M; Sathekge MM
Diagnostics (Basel); 2022 Feb; 12(3):. PubMed ID: 35328148
[TBL] [Abstract][Full Text] [Related]
12. Role of Various Metabolic Parameters Derived From Baseline 18F-FDG PET/CT as Prognostic Markers in Non-Small Cell Lung Cancer Patients Undergoing Platinum-Based Chemotherapy.
Sharma A; Mohan A; Bhalla AS; Sharma MC; Vishnubhatla S; Das CJ; Pandey AK; Sekhar Bal C; Patel CD; Sharma P; Agarwal KK; Kumar R
Clin Nucl Med; 2018 Jan; 43(1):e8-e17. PubMed ID: 29112011
[TBL] [Abstract][Full Text] [Related]
13. Metabolic parameters of pretreatment 2-[
Li C; Dong Y; Pan Y; Han Y; Zhang J; Luan X; Liu J; Xu X; Guan Z; Wang G; Xu B
Quant Imaging Med Surg; 2024 Jan; 14(1):604-617. PubMed ID: 38223061
[TBL] [Abstract][Full Text] [Related]
14. Metabolic parameters using ¹⁸F-FDG PET/CT correlate with occult lymph node metastasis in squamous cell lung carcinoma.
Kim DH; Song BI; Hong CM; Jeong SY; Lee SW; Lee J; Ahn BC
Eur J Nucl Med Mol Imaging; 2014 Nov; 41(11):2051-7. PubMed ID: 24990401
[TBL] [Abstract][Full Text] [Related]
15. [Prognostic value of pretreatment (18)F-FDG PET-CT for patients with advanced diffuse large B-cell lymphoma].
Ding CY; Guo Z; Sun J; Yang WP; Li TR
Zhonghua Zhong Liu Za Zhi; 2018 Jul; 40(7):528-533. PubMed ID: 30060362
[No Abstract] [Full Text] [Related]
16. Optimal FDG PET/CT volumetric parameters for risk stratification in patients with locally advanced non-small cell lung cancer: results from the ACRIN 6668/RTOG 0235 trial.
Salavati A; Duan F; Snyder BS; Wei B; Houshmand S; Khiewvan B; Opanowski A; Simone CB; Siegel BA; Machtay M; Alavi A
Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):1969-1983. PubMed ID: 28689281
[TBL] [Abstract][Full Text] [Related]
17. The correlation of
Qu YH; Long N; Ran C; Sun J
Clin Transl Oncol; 2021 Mar; 23(3):620-627. PubMed ID: 32683540
[TBL] [Abstract][Full Text] [Related]
18. Whole-Body Metabolic Tumor Volume, as Determined by (18)F-FDG PET/CT, as a Prognostic Factor of Outcome for Patients With Breast Cancer Who Have Distant Metastasis.
Son SH; Lee SW; Jeong SY; Song BI; Chae YS; Ahn BC; Lee J
AJR Am J Roentgenol; 2015 Oct; 205(4):878-85. PubMed ID: 26204115
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Value of Metabolic Tumor Volume and Total Lesion Glycolysis on Preoperative ¹⁸F-FDG PET/CT in Patients with Pancreatic Cancer.
Lee JW; Kang CM; Choi HJ; Lee WJ; Song SY; Lee JH; Lee JD
J Nucl Med; 2014 Jun; 55(6):898-904. PubMed ID: 24711649
[TBL] [Abstract][Full Text] [Related]
20. An Investigation of the Relationship Between 18F-FDG PET/CT Parameters of Primary Tumors and Lymph Node Metastasis in Resectable Non-small Cell Lung Cancer.
Kandemir O; Demir F
Curr Radiopharm; 2023 Aug; ():. PubMed ID: 37644744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
